-
Jan 3, 2025 | 
acrjournals.onlinelibrary.wiley.com | Lisa K Stamp |Chris Frampton |Sarah Stewart |Keith J. Petrie |N Lawrence Edwards |Angelo L. Gaffo | +1 more
Supporting Information Filename Description acr25494-sup-0001-Disclosureform.pdfPDF document, 405.2 KB Disclosure Form acr25494-sup-0002-TableS1.docxWord 2007 document , 22.4 KB Supplementary Table 1: Baseline demographics of the participants. Data are presented as n (%) or mean (SD) unless otherwise stated.
-
Dec 23, 2024 | 
acrjournals.onlinelibrary.wiley.com | Lisa K Stamp |Christopher Frampton |Jeff Newcomb |James R. O'Dell |Ted R Mikuls |Nicola Dalbeth
Supporting Information Filename Description acr25486-sup-0001-Disclosureform.pdfPDF document, 408.1 KB Disclosure Form
-
Nov 27, 2024 | 
jamanetwork.com | Yilun Wang |Nicola Dalbeth
Key PointsQuestion
How does urate-lowering therapy (ULT) affect the progression of chronic kidney disease (CKD) in patients with gout and impaired kidney function? Findings
This cohort study including 14 792 patients with gout and CKD stage 3 found that lowering serum urate level to less than 6 mg/dL using ULT was not associated with a higher risk of severe or end-stage kidney disease progression compared with those who did not achieve this level with ULT.
-
Nov 6, 2024 | 
jrheum.org | Niamh C. Fanning |John Pearson |Nicola Dalbeth |Huti Watson
AbstractObjective Evidence for an association of smoking with gout is conflicting. We assessed associations of current and past smoking with gout in an Aotearoa New Zealand (NZ) population.
-
Sep 23, 2024 | 
acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth
Supporting Information Filename Description acr25437-sup-0001-Disclosureform.docxWord 2007 document , 92.1 KB Disclosure Form acr25437-sup-0002-supinfo.docxWord 2007 document , 459.6 KB Supporting Information
-
Sep 22, 2024 | 
acrjournals.onlinelibrary.wiley.com | Suz Jack Chan |Lisa K Stamp |Gareth J Treharne |Nicola Dalbeth
INTRODUCTION Current treatment paradigms for managing rheumatoid arthritis (RA) aim to prevent joint damage and disability by frequently assessing disease activity and altering disease-modifying antirheumatic drug (DMARD) therapy to achieve either remission or low disease activity (LDA).1 Since the introduction of biologic DMARDs (bDMARDs), more people with RA are able to achieve a state of LDA or remission.2 Although bDMARDs are effective, their high cost and adverse event profile have led...
-
Aug 21, 2024 | 
jamanetwork.com | Pascal Richette |Nicola Dalbeth |Lisa K Stamp
Surrogate Markers and Clinical Outcomes Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Joshua D. Wallach, PhD, MS; Samuel Yoon, BS, BA; Harry Doernberg, MM; Laura R. Glick, MD; Oriana Ciani, PhD; Rod S. Taylor, PhD; Maryam Mooghali, MD; Reshma Ramachandran, MD, MHS, MPP; Joseph S. Ross, MD, MHS Surrogate Markers and Clinical Outcomes—Reply Joshua D. Wallach, PhD, MS; Reshma Ramachandran, MD, MPP, MHS; Joseph S.
-
Jun 2, 2024 | 
jrheum.org | Lisa K Stamp |Nicola Dalbeth |N. Dalbeth |L.K. Stamp
Key Indexing Terms:allopurinolgoutGout remains one of the most common forms of arthritis worldwide. Typically, gout presents with intermittent, intensely inflammatory gout flares, which represent the immune response to the deposition of monosodium urate (MSU) crystals within and around joints and periarticular structures.
-
May 8, 2024 | 
onlinelibrary.wiley.com | Mike Frecklington |Belinda Ihaka |Nicola Dalbeth
Corresponding Author Sarah Stewart School of Clinical Sciences, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand Whai Whakaoranga Aotearoa: Active Living and Rehabilitation: Aotearoa New Zealand, Health and Rehabilitation Research Institute, School of Clinical Sciences, Auckland University of Technology, Auckland, New Zealand Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand...
-
Apr 25, 2024 | 
nature.com | Pascal Richette |Nicola Dalbeth
Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
